In the video below, Saba Shaikh, MD, and Sanu Modi, MD, discuss newly released results from the Phase 3 DESTINY-Breast 11 clinical trial, which showed that trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer.
The Program in Progress will continue to be updated. View the current Program
